Semaglutide Treatment On Coronary Progression

Part of paid clinical trials in Torrance, California.

Sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Study ID
NCT03985384
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
40 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this research study is to see the effect of the diabetes medicine Semaglutide on a condition called atherosclerosis. Atherosclerosis is a narrowing, blockage, or hardening of the arteries due to a build up of calcium. This study will look specifically at the arteries involving the heart.

Key Dates

Start date
Apr 30, 2019
Status verified
Oct 2023
Primary completion
Dec 27, 2022
Completion
Dec 27, 2022

Study Design

Enrollment
140 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Semaglutide
    Semaglutide 2mg/1.5 ml (1.34 mg/ml) Prefilled pen for SQ injection
  • Placebo Comparator: Placebo
    Placebo 1.5 ml, pen-injector for SC injection.

Primary Outcome Measure

Rate of change in non-calcified plaque volume [ Time Frame: 12 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical CenterTorranceCalifornia90502-

Find similar trials in Torrance, CA

By condition
Type 2 diabetes
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center· Torrance, CA

Related Studies